Last update 08 May 2025

Hangzhou Hansi Biological Pharmaceutical Co., Ltd.

Private Company|2016|Zhejiang Sheng, China|
www.hanxbio.com

Overview

Tags

Neoplasms
Skin and Musculoskeletal Diseases
Other Diseases
Monoclonal antibody
Bispecific antibody
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms5
Hemic and Lymphatic Diseases2
Immune System Diseases2
Nervous System Diseases1
Top 5 Drug TypeCount
Monoclonal antibody3
Small molecule drug1
Bispecific antibody1
Top 5 TargetCount
ARK5 x CDK4 x CDK6 x CSF-1R x FLT31
PD-1 x SIRPα1
NKG2A(killer cell lectin like receptor C1)1
PD-1(Programmed cell death protein 1)1
OX40(Tumor necrosis factor receptor superfamily member 4)1

Related

6
Drugs associated with Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
Pucotenlimab
Target
PD-1
Mechanism
PD-1 inhibitors
Active Org.
Taizhou Hanzhong Biomedical Co., Ltd.Taizhou Hanzhong Biomedical Co., Ltd. [+5]
Originator Org.
Lepu Biopharma Co., Ltd.Lepu Biopharma Co., Ltd.
Active Indication
Melanoma [+16]
Inactive Indication
Anaplastic Thyroid Carcinoma [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date19 Jul 2022
Rigosertib Sodium
Target
CDK1 x Class I PI3K x PLK1
Mechanism
CDK1 inhibitors [+2]
Active Org.
Traws Pharma, Inc.Traws Pharma, Inc. [+2]
Originator Org.
Traws Pharma, Inc.Traws Pharma, Inc.
Active Indication
Melanoma [+4]
Inactive Indication
Acute Lymphoblastic Leukemia [+29]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
HX-009
Target
PD-1 x SIRPα
Mechanism
PD-1 inhibitors [+1]
Active Org.
Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
Originator Org.
Wuhan Hanxiong Biotech,inc.
Active Indication
Biliary Tract Neoplasms [+9]
Inactive Indication
Liver Cancer [+1]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
22
Clinical Trials associated with Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
NCT06708663
/ RecruitingPhase 1/2
Phase IIa Study of HX009+IN10018 in Patients with Advanced Solid Tumours, Including Biliary Tract Malignancies and Malignant Melanoma, Treated with or Without Standard Chemotherapy
NCT06703255
/ RecruitingPhase 1/2
A Phase IIa Clinical Study of HX301 Alone or in Combination with Temozolomide in Patients with High-Grade Glioma (Grade III and IV)
CTR20244298
/ RecruitingPhase 2
HX009+ IN10018 联合或不联合标准化疗治疗晚期实体瘤（包括胆道恶性肿瘤和恶性黑色素瘤）患者的 IIa 期研究
[Translation] A Phase IIa Study of HX009 + IN10018 with or without Standard Chemotherapy in Patients with Advanced Solid Tumors, Including Biliary Malignancies and Malignant Melanoma
100 Clinical Results associated with Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
2
2
Phase 2 Clinical
Phase 3 Clinical
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Pucotenlimab
 ( PD-1 )		Gastrooesophageal junction cancer
More
Phase 3
HX-009
 ( PD-1 x SIRPα )		Melanoma
More
Phase 2
Narazaciclib
 ( ARK5 x CDK4 x CDK6 x CSF-1R x FLT3 )		Glioblastoma
More
Phase 2
HX017
 ( NKG2A )		Neoplasms
More
Preclinical
HX011
 ( OX40 )		Neoplasms
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free